Intermittent drug techniques refer to the "use of medication only during periods of incipient relapse or symptom exacerbation rather than continuously." The aim is to reduce the risk of adverse effects of antipsychotics by "reducing longterm medication exposure for patients who are receiving maintenance treatment while limiting risk of relapse," with a further goal of improving social functioning resulting from the reduction of antipsychotic-induced side effects. We reviewed the effects of different intermittent drug techniques compared with maintenance treatment in people with schizophrenia or related disorders. We searched The Cochrane Schizophrenia Group Trials register (april 2012) and supplemented this by contacting relevant study authors and manually searching reference lists. all relevant randomized controlled trials (rCTs) were included.of 241 records retrieved by the search, 17 trials were included. homogenous data demonstrated that instances of relapse were significantly higher in people receiving any intermittent drug treatment in the long term (n=436, 7 rCTs, rr=2.46, 95% CI=1.70-to 3.54). Intermittent treatment was shown to be more effective than placebo, however, and demonstrated that significantly less people receiving intermittent antipsychotics experienced full relapse by medium term (n=290, 2 rCTs, rr=0.37, 95% CI=0.24-0.58). Intermittent antipsychotic treatment is not as effective as continuous, maintained antipsychotic therapy for preventing relapse in people with schizophrenia. It does seem, however, significantly better than no treatment.

Background Transdermal delivery of drugs is a quite challenging task for pharmaceutical scientists. The transdermal route is preferred over the oral route due to various advantages like avoidance of the first-pass effect, non-invasiveness, and high patient compliance. Therefore, it is necessary to develop an effective carrier system that enables the effective passage of the drug through the dermal barrier. Main body of abstract Various novel drug delivery systems are used to enhance the permeation of a variety of drugs through the skin barrier. Researchers around the globe have explored nanofibers for the transdermal delivery of various therapeutic agents. Nanofibers are designed to have a high concentration of therapeutic agents in them promoting their flux through various skin layers. Polymeric nanofibers can be explored for the loading of both hydrophilic and lipophilic drugs. Biopolymer-based nanofibers have been also explored for transdermal delivery. They are capable of controlling the release of therapeutic agents for a prolonged time. Short conclusion The literature presented in this review paper provides significant proof that nanofibers will have an intense impact on the transdermal delivery of different bioactive molecules in the future. Graphic abstract

No abstract

No abstract

No abstract